Antibody Drug Conjugates Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends | Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline PLC

Overview and Scope
Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells. As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell.

Sizing and Forecast
The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $8.78 billion in 2023 to $10.7 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%.  The  growth in the historic period can be attributed to increasing prevalence of cancer, clinical success and approvals, strategic collaborations, growing investment in r&d, market expansion strategies.

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%.  The growth in the forecast period can be attributed to next-generation adcs, expanding indications, increasing focus on personalized medicine, rising investment in precision medicine, increasing healthcare awareness. Major trends in the forecast period include advancements in conjugation technologies, improved understanding of tumor biology, technological advancements, expanding therapeutic application, advanced conjugation technologies.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Segmentation & Regional Insights
The antibody drug conjugates market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Product: Adcertis, Kadcyla, Other Products
3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
5) By End User: Hospital, Clinics, Other End Users

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2023. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp

Major Driver Impacting Market Growth
The antibody-drug conjugates market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody-drug conjugates, driving the market’s growth.

Key Industry Players
Major companies operating in the antibody drug conjugates market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Progenics Pharmaceuticals Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Fredax, Eisai Co. Ltd., Merck KGaA, Bracco S.p.A.

The antibody drug conjugates market report table of contents includes:
1. Executive Summary
2. Antibody Drug Conjugates Market Characteristics
3. Antibody Drug Conjugates Market Trends And Strategies
4. Antibody Drug Conjugates Market – Macro Economic Scenario
5. Global Antibody Drug Conjugates Market Size and Growth
………..
32. Global Antibody Drug Conjugates Market Competitive Benchmarking
33. Global Antibody Drug Conjugates Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Antibody Drug Conjugates Market
35. Antibody Drug Conjugates Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:
https://topprnews.com/surge-arrester-market-forecast/
https://topprnews.com/surgical-retractors-market-outlook/
https://topprnews.com/sweet-potatoes-market-forecast/
https://goodprnews.com/surge-arrester-market-research/
https://goodprnews.com/surgical-retractors-market-growth/
https://goodprnews.com/sweet-potatoes-market-trends/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model